ORCHESTRA BIOMED HOLDINGS, INC.

Highlights Orchestra BioMed Holdings, Inc.

Equities

OBIO

US68572M1062

Market Closed - Nasdaq Other stock markets 15:59:47 2024-06-04 EDT			5-day change	1st Jan Change
7.9 ^USD	+10.64%		+13.34%	-13.47%

05-13	Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000	MT
05-13	Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000	05-13	MT
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	04-30	CI
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	03-13	CI
Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients	03-06	CI
Orchestra Biomed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with Avim Therapy for over 3 Years	02-26	CI
Orchestra Biomed Announces Initiation of Backbeat Pivotal Study of Avim Therapy in Hypertensive Pacemaker Patients	01-08	CI
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q3 Revenue $419,000	11-13	MT
Orchestra BioMed Gets FDA Approval to Begin Study of BackBeat CNT for Hypertension in Pacemaker Patients; Shares Jump	23-09-19	MT
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q2 Revenue $915,000	23-08-10	MT
Orchestra Biomed Holdings, Inc. Receives Fda Approval of Ide for U.S. Pivotal Study of Virtue(R) Sirolimus Angioinfusion Balloon in Patients with Coronary In-Stent Restenosis	23-08-08	CI
Orchestra BioMed Holdings, Inc. Announces CFO Changes	23-06-07	CI
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy	23-06-07	CI
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Posts Q1 Revenue $1.2M	23-05-12	MT
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Orchestra BioMed, Inc. completed the acquisition of Health Sciences Acquisitions Corporation 2 from HSAC 2 Holdings, LLC, RTW Investments, LP and others in a reverse merger transaction.	23-01-25	CI
Orchestra BioMed, Inc. entered into an agreement and plan of merger agreement to acquire Health Sciences Acquisitions Corporation 2 from HSAC 2 Holdings, LLC, RTW Investments, LP and others for $93 million.	22-07-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer